PDF herunterladen
Thromb Haemost 1984; 52(02): 144-147
DOI: 10.1055/s-0038-1661159
Original Article
Schattauer GmbH Stuttgart

Association Between Bleeding Time and Platelet Adherence to Artery Subendothelium

K S Sakariassen
1   The Department of Haematology, University Hospital Utrecht, The Netherlands
,
P A Bolhuis
1   The Department of Haematology, University Hospital Utrecht, The Netherlands
,
Margaretha Blombäck
3   The Department of Blood Coagulation Disorders, Karolinska Sjukhuset, Stockholm, Sweden
,
L Thorell
2   The Department of Blood Coagulation Research, Karolinska Instituted Stockholm, Sweden
,
Birger Blombäck
2   The Department of Blood Coagulation Research, Karolinska Instituted Stockholm, Sweden
,
J J Sixma
1   The Department of Haematology, University Hospital Utrecht, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 10. April 1984

Accepted 02. Juli 1984

Publikationsdatum:
19. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

The efficacy of five different factor VUI-von Willebrand factor (FVIII-VWF) preparations in mediating adherence of blood platelets to damaged vessel walls was tested in an annular perfusion chamber utilizing human arteries and reconstituted blood.

FVIII-VWF-purified by Sepharose CL-4B chromatography and von Willebrand factor prepared from this preparation by dissociation with 0.25 M CaCl2 followed by Sepharose CL-6B chromatography were equally effective in mediating platelet adherence as FVIII-VWF in cryoprecipitate and in plasma from normal subjects. A commercial concentrate of FVIII-VWF (Hemofil, Hyland) used for the treatment of haemophiliacs did not mediate platelet adherence at normal levels of FVIII-VWF related properties. A recently developed high-purity FVIII-VWF preparation (Concentrate II) containing multimers of high molecular weight normalized the platelet adherence. Platelet adherence in plasma obtained from two patients with von Willebrand’s disease (VWD) was impaired, but plasma samples obtained following treatment with Concentrate II mediated normal platelet adherence. The normalization of platelet adherence paralleled the normalization of the bleeding time.

This platelet adherence assay offers an inexpensive and efficient in vitro tool to test the efficacy of FVIII-VWF preparations designed for VWD patients. Preparations such as cryoprecipitate and Concentrate II mediated the platelet adherence and normalized the bleeding time. The commercial preparation did not mediate platelet adherence and had no effect on the bleeding time.

Keywords

Platelet adherence - Bleeding time - Von Willebrand’s disease - FVIII-von Willebrand factor
 

  • References

  • 1 Van Mourik JA, Bouma BN, Labruyére WT, de Graaf S, Mochtar IA. Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res 1974; 4: 155-164
    CrossrefPubMedGoogle Scholar
  • 2 Zimmerman TS, Roberts J, Edgington TS. Factor VIII related antigen: Multiple molecular forms in plasma. Proc Nat Acad Sci USA 1975; 72: 5121-5125
    CrossrefPubMedGoogle Scholar
  • 3 Counts RB, Paskell SL, Elgee SK. Disulfide bonds and the quaternary structure of factor VIII: von Willebrand factor. J Clin Invest 1978; 62: 702-709
    CrossrefPubMedGoogle Scholar
  • 4 Van Mourik J, Bolhuis PA. Dispersity of human factor VIII-von Willebrand factor. Thromb Res 1978; 13: 15-24
    CrossrefPubMedGoogle Scholar
  • 5 Owen WG, Wagner RH. Antihemophilic factor: Separation of an active fragment following dissociation by salts or detergents. Thrombos Diathes Haemorrh 1972; 27: 502-515
    PubMedGoogle Scholar
  • 6 Weiss HJ, Phillips LL. Separation of subunits of antihaemophilic factor (AHF) by agarose gel chromatography. Thrombos Diathes Haemorrh 1972; 27: 212-219
    PubMedGoogle Scholar
  • 7 Bouma BN, Wiegerinck Y, Sixma JJ, van MourikJ, Mochtar IA. Immunological characterization of purified antihemophilic factor A (Factor VIII) which corrects abnormal platelet retention in von Willebrand’s disease. Nature New Biol 1972; 236: 104-106
    CrossrefPubMedGoogle Scholar
  • 8 Rick ME, Hoyer LW. Immunologic studies of antihemophilic factor (AHF factor VIII). V. Immunologic properties of AHF subunit produced by salt dissociation. Blood 1973; 42: 737-747
    PubMedGoogle Scholar
  • 9 Bouma BN, Dodds WJ, van MourikJ, Sixma JJ, Wester WP. Infusion of human and canine factor VIII in dogs with von Willebrand’s disease: Studies of the von Willebrand and factor VIII synthesis stimulating factors. Scand J Haematol 1976; 17: 263-275
    PubMedGoogle Scholar
  • 10 Patek AJ, Taylor FH C. Hemophilia II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest 1937; 16: 113-124
    CrossrefPubMedGoogle Scholar
  • 11 Nilsson IM, Blombäck M, Jorpes E, Blombäck B, Johannsson SA. Von Willebrand’s disease and its correction with human plasma fraction I-O. Acta Med Scand 1957; 159: 179-188
    PubMedGoogle Scholar
  • 12 Zimmerman TS, Ruggeri ZM. Von Willebrand’s disease. In: Spaet TH. (ed) Progress in Hemostasis and Thrombosis. Grune & Stratton Inc; New York: 1982. 6 203
    Google Scholar
  • 13 Jørgensen L, Borchgrevink CF. The haemostatic mechanism in patients with haemorrhagic disease. Acta Pathol Microbiol Scand 1964; 60: 55-82
    CrossrefPubMedGoogle Scholar
  • 14 Hovig T, Stormorken H. Ultrastructural studies on the platelet formation in bleeding time wounds from normal individuals and patients with von Willebrand’s disease. Acta Pathol Microbiol Scand 1974; 248: 105-122
    PubMedGoogle Scholar
  • 15 Tschopp TB, Weiss HJ, Baumgartner HR. Decreased adhesion of platelets to subendothelium in von Willebrand’s disease. J Lab Clin Med 1974; 83: 296-300
    PubMedGoogle Scholar
  • 16 Sakariassen KS, Cattaneo M, Berg Av d, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 229-236
    PubMedGoogle Scholar
  • 17 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VHI-von Willebrand factor bound to the subendothelium. Nature 1979; 297: 636-638
    PubMedGoogle Scholar
  • 18 Cornu P, Larrieu MJ, Caen J, Bernard J. Transfusion studies in von Willebrand’s disease: Effect on bleeding time and factor VIII. Br J Haematol 1963; 9: 189-202
    CrossrefPubMedGoogle Scholar
  • 19 Bennet B, Dormandy K. Pool’s cryoprecipitate and exhausted plasma in the treatment of von Willebrand’s disease and factor XI deficiency. Lancet 1966; 2: 731-732
    PubMedGoogle Scholar
  • 20 Perkins PA. Correction of the hemostatic defects in von Willebrand’s disease. Blood 1967; 30: 375-380
    PubMedGoogle Scholar
  • 21 Blatt PhM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand’s disease. Dissociation of bleeding time factor and ristocetin cofactor activities JAMA 1976; 236: 2770-2772
    CrossrefPubMedGoogle Scholar
  • 22 Green D, Potter EV. Failure of AHF concentrate to control bleeding in von Willebrand’s disease. Am J Med 1976; 60: 357-360
    CrossrefPubMedGoogle Scholar
  • 23 Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to human artery subendothelium. Effect of factor VIII-von Willebrand factor of various multimeric composition Blood 1984; 63: 128-139
    PubMedGoogle Scholar
  • 24 Thorell L, Blombäck M, Blombäck B. An in vivo study of a new factor VIII, high purity, preparation. Thromb Res 1983; 31: 375-385
    CrossrefPubMedGoogle Scholar
  • 25 Duke VW. The relation of blood platelets to hemorrhagic disease: Description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA 1910; 55: 1185-1192
    CrossrefPubMedGoogle Scholar
  • 26 Ivy AC, Shapiro PF, Melnick P. The bleeding time in jaundice. Surg Gynecol Obstet 1935; 60: 781-784
    PubMedGoogle Scholar
  • 27 Van Mourik J, Mochtar IA. Purification of human antihemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta 1970; 221: 677-679
    CrossrefPubMedGoogle Scholar
  • 28 Bolhuis PA, Sakariassen KS, Sander HJ, Bouma BN, Sixma JJ. Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 1981; 97: 568-576
    PubMedGoogle Scholar
  • 29 Thorell L, Blomback B. Purification of the factor VIII complex. Thromb Res. 1984 (in press)
    PubMedGoogle Scholar
  • 30 Veltkamp JJ, Drion EF, Loeliger EA. Detection of the carrier state in hereditary coagulation disorders. I. Thrombos Diathes Haemorrh 1968; 19: 279-303
    PubMedGoogle Scholar
  • 31 Bouma BN, Starkenburg AE. Diluton of haemophilic plasma used as a reagent in the determination of anti-hemophilic factor A (factor VIII). Haemostasis 1974; 3: 94-97
    PubMedGoogle Scholar
  • 32 Veltkamp JJ, van TilburgN H. Detection of heterozygotes of recessive von Willebrand’s disease by the assay of antihemophilic- factor-like antigen. N Engl J Med 1973; 289: 882-885
    CrossrefPubMedGoogle Scholar
  • 33 MacFarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin factor). Thrombos Diathes Haemorrh 1975; 34: 306-308
    PubMedGoogle Scholar
  • 34 Over JN, Bouma BN, van MourikJ, Sixma JJ, Vlooswijk RA, Bakker-Woudenberg IHeterogeneity. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med 1978; 91: 32-46
    PubMedGoogle Scholar
  • 35 Aarts PA M M, Bolhuis PA, Sakariassen KS, Heethaar RM, Sixma JJ. Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood 1983; 62: 214-217
    PubMedGoogle Scholar
  • 36 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-179
    CrossrefPubMedGoogle Scholar
  • 37 Sakariassen KS, Bolhuis PA, Sixma JJ. Platelet adherence to subendothelium of human arteries in pulsatile and steady flow. Thromb Res 1980; 415: 547-559
    PubMedGoogle Scholar
  • 38 Sakariassen KS, Ottenhof-Rovers H, Sixma JJ. Factor VIII-von Willebrand factor requires calcium for facilitation of platelet adherence. Blood 1984; 63: 996-1003
    PubMedGoogle Scholar
  • 39 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear-dependent decrease of adherence in von Willebrand’s disease and the Bemard-Soulier syndrome. J Lab Clin Med 1978; 92: 750-764
    PubMedGoogle Scholar